BioScrip Inc. (NASDAQ:BIOS) shares saw an uptick in trading volume on Friday . 9,156,848 shares were traded during trading, an increase of 562% from the previous session’s volume of 1,383,648 shares.The stock last traded at $2.56 and had previously closed at $2.65.

Separately, Zacks Investment Research upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Friday, June 17th.

The company’s market capitalization is $176.08 million. The stock has a 50-day moving average price of $2.57 and a 200-day moving average price of $2.31.

BioScrip (NASDAQ:BIOS) last issued its earnings results on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.05. The business had revenue of $238.50 million for the quarter, compared to analysts’ expectations of $232.38 million. The firm’s revenue for the quarter was down 2.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.17) EPS. On average, equities analysts anticipate that BioScrip Inc. will post ($0.20) earnings per share for the current year.

In other BioScrip news, Director Coliseum Capital Management, L bought 4,200,000 shares of the business’s stock in a transaction on Wednesday, June 22nd. The stock was purchased at an average price of $2.00 per share, for a total transaction of $8,400,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David W. Golding bought 12,500 shares of the business’s stock in a transaction on Friday, June 17th. The shares were acquired at an average price of $2.48 per share, with a total value of $31,000.00. Following the transaction, the director now directly owns 42,500 shares of the company’s stock, valued at $105,400. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in BioScrip stock. Diamond Hill Capital Management Inc. increased its stake in shares of BioScrip Inc. (NASDAQ:BIOS) by 2.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,055,476 shares of the company’s stock after buying an additional 74,757 shares during the period. Diamond Hill Capital Management Inc. owned about 4.44% of BioScrip worth $5,347,000 as of its most recent SEC filing.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.